|
|
BRIEF REPORT |
|
Year : 2007 | Volume
: 55
| Issue : 6 | Page : 457-458 |
|
Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks
Nishant Sachdev, Kavitha Vishwanathan, Vishali Gupta, Ramandeep Singh, Amod Gupta
Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Date of Submission | 08-Aug-2006 |
Date of Acceptance | 28-Sep-2006 |
| |
Correspondence Address: Amod Gupta Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh - 160 012 India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/0301-4738.36482
Angioid streaks are crack-like dehiscences in the Bruch's membrane, which predispose to the development of a choroidal neovascular membrane (CNVM) that carries a poor visual outcome. We report successful treatment in a 25-year-old woman with bilateral angioid streaks and subfoveal CNVM in the left eye who received two doses of intravitreal bevacizumab (1.25 mg) injections six weeks apart, resulting in rapid regression of the CNVM. Keywords: Angioid streaks, intravitreal bevacizumab, subfoveal choroidal neovascular membrane
How to cite this article: Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol 2007;55:457-8 |
Angioid streaks are the result of a crack-like dehiscence in the Bruch's membrane, which itself is brittle and calcified, and are seen as linear gray lesions radiating from the peripapillary area. [1] Visual impairment often occurs as a result of a subfoveal choroidal neovascular membrane (CNVM) with subsequent serous and hemorrhagic detachment of the overlying neurosensory retina. These neovascular membranes associated with angioid streaks present a major challenge in management. Argon laser treatment of the CNVM shows a drop in visual acuity (VA) with high rates of recurrence and persistence. [2] Photodynamic therapy using verteporfin has been tried extensively in such eyes with very poor results with most eyes undergoing enlargement and disciform transformation of the neovascularization process. [3],[4] Poor success and high recurrence rates have been seen after submacular surgery for removal of CNVM in such cases. [5] In this case report, we present a case of CNVM associated with angioid streaks treated with intravitreal bevacizumab, an anti-vascular endothelial growth factor (VEGF) molecule.
Case Report | | |
A 25-year-old woman presented with progressive blurring of vision in the left eye of two months duration. There was no history of any systemic illness or previous ocular trauma. Ocular examination revealed a best corrected VA of 20/20 in the right eye and 20/40 in the left eye. The pupillary reactions as well as the slit-lamp biomicroscopic examination of the anterior segment were normal in both the eyes. The posterior segment findings included bilateral, multiple, grayish, subretinal, linear branching streaks extending centrifugally from the peripapillary area and multiple areas of "Peau d'orange" pigmentary changes in the temporal midperipheral fundus. In the left eye one of these streaks passed through the fovea and was associated with a small, grayish, subfoveal lesion with a surrounding bleed [Figure - 1]A.
Fundus fluorescein angiography showed transmission hyperfluorescence corresponding to the linear streaks and an area of expanding hyperfluorescence, with late leakage in the subfoveal location in the left eye [Figure - 1]B. Optical coherence tomography (OCT) confirmed the presence of a subfoveal CNVM with a central retinal thickness (CRT) of 392 microns in the left eye [Figure - 2]A.
A detailed systemic workup revealed the presence of multiple hyperpigmented papules on the back of the neck with a highly elastic skin, suggestive of pseudoxanthoma elasticum.
After an informed consent, 1.25 mg intravitreal bevacizumab (Avastin TM , Genetech INA, California, USA) was injected in the left eye under aseptic conditions. Post-injection, her best corrected visual acuity improved to 20/30 and the CRT on OCT reduced to 331 microns at one week and to 211 microns at six weeks. Fundus fluorescein angiogram confirmed reduction in leakage [Figure - 1]C.
A second dose of intravitreal bevacizumab (1.25 mg) was repeated six weeks after the first injection. Two weeks after the second dose, her best corrected visual acuity improved to 20/20. Fluorescein angiogram confirmed total absence of any leakage [Figure - 1]D with CRT of 190 microns on OCT [Figure - 2]B.
Discussion | | |
Most patients with angioid streaks may remain asymptomatic till development of subfoveal CNVM or a choroidal rupture which carries an extremely poor visual prognosis whether treated or not. [2],[3],[4],[5]
Recently, vascular endothelial growth factor (VEGF) has been implicated in the pathogenesis of CNVM. [6] Bevacizumab is a humanized monoclonal antibody that inhibits all isoforms of VEGF and is FDA-approved for the treatment of colorectal cancer. [7] Recently, bevacizumab has been used to treat CNVM due to age-related macular degeneration (ARMD). [8],[9] These exudative ARMD patients treated with two or three injections of intravitreal bevacizumab showed marked improvement in visual acuity with reduction in angiographic leakage and CRT after 12 weeks of follow-up. These studies showed no untoward effects even after three injections.
As development of CNVM in angioid streaks may also involve similar mechanisms of neovascularization, it prompted us for a trial of the above drug. A literature review using MEDLINE failed to reveal any mention of a case of choroidal neovascularization due to angioid streaks treated with intravitreal bevacizumab. This case illustrates that intravitreal bevacizumab has a possible role in the treatment of the above condition with regression of neovascular membrane and subsequent visual improvement, although a much longer follow-up and a large prospective study is required to reach a conclusive result.
References | | |
1. | Shields JA, Federman JL, Tomer TL, Annesley WH Jr. Angioid streaks. I. Ophthalmoscopic variations and diagnostic problems. Br J Ophthalmol 1975;59:257-66. |
2. | Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 1993;116:414-23. [ PUBMED] |
3. | Shaikh S, Ruby AJ, Williams GA. Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks. Am J Ophthalmol 2003;135:1-6. [ PUBMED] [ FULLTEXT] |
4. | Arias L, Pujol O, Rubio M, Caminal J. Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks. Graefes Arch Clin Exp Ophthalmol 2006;244:753-7. [ PUBMED] [ FULLTEXT] |
5. | Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994;101:1384-96. [ PUBMED] |
6. | Hangai M, Murata T, Miyawaki N, Spee C, Lim JI, He S, et al . Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001;42:1617-25. [ PUBMED] [ FULLTEXT] |
7. | Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, et al . Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006;24:3354-60. [ PUBMED] [ FULLTEXT] |
8. | Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9. [ PUBMED] [ FULLTEXT] |
9. | Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72. [ PUBMED] [ FULLTEXT] |
[Figure - 1], [Figure - 2]
This article has been cited by | 1 |
One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation |
|
| Sumit Randhir Singh, Adrian T Fung, Samantha Fraser-Bell, Marco Lupidi, Sashwanthi Mohan, Pierre-Henry Gabrielle, Dinah Zur, Matias Iglicki, Paula M López-Corell, Roberto Gallego-Pinazo, Cláudia Farinha, Luiz H Lima, Ahmad M Mansour, Antonio Marcello Casella, Lihteh Wu, Rufino Silva, Sami H Uwaydat, Vishal Govindahari, Jose Fernando Arevalo, Jay Chhablani | | British Journal of Ophthalmology. 2020; 104(5): 678 | | [Pubmed] | [DOI] | | 2 |
Membrana neovascular subretiniana asociada a estrías angioides tratada con bevacizumab intravítreo |
|
| A. García-López,C. González-Castaño | | Archivos de la Sociedad Española de Oftalmología. 2013; | | [Pubmed] | [DOI] | | 3 |
LONG-TERM OUTCOMES OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION IN PSEUDOXANTHOMA ELASTICUM |
|
| JANE S. MYUNG,PAWAN BHATNAGAR,RICHARD F. SPAIDE,JAMES M. KLANCNIK,MICHAEL J. COONEY,LAWRENCE A. YANNUZZI,K. BAILEY FREUND | | Retina. 2010; 30(5): 748 | | [Pubmed] | [DOI] | | 4 |
ANGIOID STREAK-RELATED CHOROIDAL NEOVASCULARIZATION TREATED BY INTRAVITREAL RANIBIZUMAB : |
|
| Francesco Boscia, Salvatore Cillino, Maria Vadalà, Alfredo Pece, Stefano Cipolla, Carla Monteleone, Federico Ricci | | Retina. 2010; 30(6): 903 | | [VIEW] | [DOI] | | 5 |
INTRAVITREAL RANIBIZUMAB TREATMENT OF MACULAR CHOROIDAL NEOVASCULARIZATION SECONDARY TO ANGIOID STREAKS : One-Year Results of a Prospective Study |
|
| Ioannis D Ladas, Athanasios I Kotsolis, Dimitrios S Ladas, Maria Niskopoulou, Ilias Georgalas, Dimitrios Papakonstantinou, Alexandros A Rouvas | | Retina. 2010; 30(8): 1185 | | [VIEW] | [DOI] | | 6 |
Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks |
|
| Pece, A., Russo, G., Ricci, F., Isola, V., Introini, U., Querques, G. | | Clinical Ophthalmology. 2010; 4(1): 525-530 | | [Pubmed] | | 7 |
Clinical manifestations of idiopathic angioid streaks |
|
| Gao, Y., Jiang, X., Zhang, Y., Liu, F., Song, R. | | Chinese Ophthalmic Research. 2010; 28(4): 342-346 | | [Pubmed] | | 8 |
Treatment of angioid streaks with Bevacizumab | [Liečba Angioid streaks (lakové trhliny) pomocou anti-VEGF] |
|
| Černák, M., Markovic, O., Černák, A. | | Ceska a Slovenska Oftalmologie. 2010; 66(2): 72-75 | | [Pubmed] | | 9 |
Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum |
|
| Myung, J.S., Bhatnagar, P., Spaide, R.F., Klancnik Jr., J.M., Cooney, M.J., Yannuzzi, L.A., Freund, K.B. | | Retina. 2010; 30(5): 748-755 | | [Pubmed] | | 10 |
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin®) for treatment of angoid streaks in pseudoxanthoma elasticum |
|
| Martin Ganssauge, Helmut Wilhelm, Karl-Ulrich Bartz-Schmidt, Sabine Aisenbrey | | Graefe s Archive for Clinical and Experimental Ophthalmology. 2009; 247(12): 1707-1710 | | [Pubmed] | [DOI] | | 11 |
Bevacizumab (Avastin) for the Treatment of Ocular Disease |
|
| Gunther, J.B., Altaweel, M.M. | | Survey of Ophthalmology. 2009; 54(3): 372-400 | | [Pubmed] | | 12 |
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration |
|
| Ciulla, T.A., Rosenfeld, P.J. | | Current Opinion in Ophthalmology. 2009; 20(3): 166-174 | | [Pubmed] | | 13 |
Fluorescein angiography characteristics and clinical manifestations of vessel-like stripes features of fundus on 13 cases |
|
| Gao, Y.-X., Jiang, X.-Q., Zhang, Y.-Q., Liu, F.-Y. | | International Journal of Ophthalmology. 2009; 9(4): 722-724 | | [Pubmed] | | 14 |
Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: A case series |
|
| Donati, M.C. and Virgili, G. and Bini, A. and Giansanti, F. and Rapizzi, E. and Giacomelli, G. and Menchini, U. | | Ophthalmologica. 2009; 223(1): 24-27 | | [Pubmed] | | 15 |
Bevacizumab (Avastin) for the Treatment of Ocular Disease |
|
| Jonathan B. Gunther,Michael M. Altaweel | | Survey of Ophthalmology. 2009; 54(3): 372 | | [Pubmed] | [DOI] | | 16 |
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration |
|
| Thomas A Ciulla,Philip J Rosenfeld | | Current Opinion in Ophthalmology. 2009; 20(3): 166 | | [Pubmed] | [DOI] | | 17 |
Management of choroidal vascularisation |
|
| Lommatzsch, A. | | British Medical Journal. 2008; 92(4): 445-446 | | [Pubmed] | |
|
|
|
|